Neurescue

Executive Summary

Neurescue is a Danish medical device company addressing a critical gap in emergency cardiovascular care. Its NEURESCUE device is the first and only CE-marked treatment specifically approved for non-shockable cardiac arrest, a condition that accounts for ~70% of cardiac arrests and has extremely low survival rates. The device employs aortic balloon occlusion to augment blood flow to the heart and brain during resuscitation, potentially improving neurologically intact survival. Founded in 2017 and based in Copenhagen, Neurescue targets a large unmet need in pre-hospital and hospital settings, with the global cardiac arrest market expected to exceed $10 billion by 2030. The company has achieved regulatory approval in Europe and is now focusing on clinical evidence generation and market expansion. Key priorities include building a robust clinical data package to support adoption and reimbursement in major EU markets, and pursuing US FDA clearance, which would unlock the largest medical device market. Neurescue's technology has the potential to become standard of care for non-shockable cardiac arrest, and recent strategic partnerships or funding rounds could accelerate its trajectory. The company is at an inflection point, with upcoming clinical and regulatory milestones likely to drive significant value.

Upcoming Catalysts (preview)

• H1 2027First pivotal clinical trial results in non-shockable cardiac arrest60% success
• Q4 2026FDA IDE submission or breakthrough device designation50% success
• H2 2026Commercial partnership or distribution deal in EU/US70% success